BridgeBio
Overview
BridgeBio is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative genetic therapies and precision medicines for serious diseases. The company leverages advanced molecular and genetic testing insights to identify patient populations most likely to benefit from targeted therapeutic interventions.
More in Genetic Testing
Latest industry news
Guardant Health's FDA-Cleared Genomic-Epigenomic Liquid Biopsy Panel Reshapes the Oncology Testing Landscape
2026-10-29 · Product
CSF DNA Testing Poised to Transform Brain Tumor Diagnosis
2026-10-28 · Research
Tempus AI Wins FDA Clearance for Pulmonary Hypertension Diagnostic Tool, Expanding Its Clinical AI Footprint
2026-10-27 · Product
Vietnam's Gene Solutions Eyes Hong Kong IPO to Fuel Regional Genomics Expansion
2026-10-26 · Industry
Company details
Category
🧬 Genetic Testing
Funding
Private
Listed
2026-07-29
Is this your company?
Claim this listing to add your logo, full description, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach genomics professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →